UPDATE 1-Novo Nordisk reports Tresiba insulin achieves target in study

COPENHAGEN, Nov 29 (Reuters) - Novo Nordisk's long-acting insulin blockbuster Tresiba has a safe cardiovascular profile and reduces episodes of severely low blood glucose levels in patients with type 2 diabetes, the Denmark-based company said on Tuesday.